Ablation for Atrial Fibrillation in Patients With Rare Pathogenic Variants in Cardiomyopathy and Arrhythmia Genes
Majd A El-Harasis,Zachary T Yoneda,Katherine C Anderson,Fei Ye,Joseph A Quintana,J Roberto Martinez-Parachini,Gregory G Jackson,Bibin T Varghese,Diane M Crawford,Lili Sun,Hollie L Williams,Matthew J O'Neill,Giovanni E Davogustto,James L Laws,Brittany S Murphy,Kelsey Tomasek,Yan Ru Su,Emily McQuillen,Emma Metz,Carly Smith,Doug Stubbs,Dakota D Grauherr,Quinn S Wells,Gregory F Michaud,Pablo Saavedra,Juan Carlos Estrada,Travis D Richardson,Sharon T Shen,Arvindh N Kanagasundram,Jay A Montgomery,Harikrishna Tandri,Christopher R Ellis,George H Crossley,Prince J Kannankeril,Lynne W Stevenson,William G Stevenson,Steven A Lubitz,Patrick T Ellinor,Dan M Roden,M Benjamin Shoemaker
DOI: https://doi.org/10.1016/j.jacep.2024.06.035
2024-08-20
Abstract:Background: Patients with rare, pathogenic cardiomyopathy (CM) and arrhythmia variants can present with atrial fibrillation (AF). The efficacy of AF ablation in these patients is unknown. Objective: This study tested the hypotheses that: 1) patients with a pathogenic variant in any CM or arrhythmia gene have increased recurrence following AF ablation; and 2) patients with a pathogenic variant associated with a specific gene group (arrhythmogenic left ventricular CM [ALVC], arrhythmogenic right ventricular CM, dilated CM, hypertrophic CM, or a channelopathy) have increased recurrence. Methods: We performed a prospective, observational, cohort study of patients who underwent AF catheter ablation and whole exome sequencing. The primary outcome measure was ≥30 seconds of any atrial tachyarrhythmia that occurred after a 90-day blanking period. Results: Among 1,366 participants, 109 (8.0%) had a pathogenic or likely pathogenic (P/LP) variant in a CM or arrhythmia gene. In multivariable analysis, the presence of a P/LP variant in any gene was not significantly associated with recurrence (HR 1.15; 95% CI 0.84-1.60; P = 0.53). P/LP variants in the ALVC gene group, predominantly LMNA, were associated with increased recurrence (n = 10; HR 3.75; 95% CI 1.84-7.63; P < 0.001), compared with those in the arrhythmogenic right ventricular CM, dilated CM, hypertrophic CM, and channelopathy gene groups. Participants with P/LP TTN variants (n = 46) had no difference in recurrence compared with genotype-negative-controls (HR 0.93; 95% CI 0.54-1.59; P = 0.78). Conclusions: Our results support the use of AF ablation for most patients with rare pathogenic CM or arrhythmia variants, including TTN. However, patients with ALVC variants, such as LMNA, may be at a significantly higher risk for arrhythmia recurrence.